FoldRx Pharmaceuticals

FoldRx Pharmaceuticals, Inc. focuses on developing first-class disease-modifying small molecule therapies to treat protein misfolding and aggregation (amyloidosis) diseases. The company's pipeline includes an advanced clinical development program for treating hereditary neurological and cardiovascular diseases, transthyretin (TTR) amyloid polyneuropathy (ATTR-PN), TTR amyloid cardiomyopathy (ATTR-CM), as well as a discovery program for Parkinson's disease and cystic fibrosis.